On Monday, the U.S. Food and Drug Administration (FDA) approved Abbott Laboratories’ (NYSE: ABT) Volt PFA System to treat patients battling atrial fibrillation (AFib). AFib is the most common type of ...

(RTTNews) - Abbott (ABT) Thursday announced it has received CE Mark in Europe for the Volt PFA System to treat patients battling atrial fibrillation (AFib). With the earlier-than-expected CE Mark, ...

Abbott's Volt™ PFA System is designed to provide a new therapy option for people battling heart rhythm disorders such as atrial fibrillation Pulsed field ablation – or PFA – uses high energy ...

Abbott ABT recently announced CE Mark approval for the Volt Pulsed Field Ablation (“PFA”) system to treat patients battling atrial fibrillation (AFib). The development came earlier than expected, ...

Announcing major milestones for the company’s suite of pulse field ablation (PFA) devices in electrophysiology, Abbott Laboratories said it is advancing treatment for patients with abnormal heart ...

Long-term data from the Volt CE Mark Study show strong results out to 12 months in patients receiving pulsed field ablation (PFA) therapy with the Volt™ PFA System The 12-month results of the Volt CE ...

Enrollment completed ahead of schedule in the global IDE for Abbott's Volt™ PFA System Global FOCALFLEX trial now underway for Abbott's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ Advisor™ HD ...

Two years after the U.S. FDA approved the first pulsed field ablation system, Abbott Laboratories finally got the regulatory nod for its Volt PFA system. Abbott follows Medtronic plc, Boston ...